ArticleCell host & microbe2007
Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner.
Article in Cell host & microbe, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 131 citations in OpenAlex.
- Antibodies Produced in Response to a Live-Attenuated Dengue Vaccine Are Functional in Activating the Complement System.The Journal of infectious diseases · 2023Trial
- Antibody-Dependent Enhancement in Flavivirus Infections: From Fc Receptor Signaling to Vaccine and Therapeutic Design.Viruses · 2026Review
- Mapping immune responses to TAK-003 dengue vaccine: immunogenicity across the clinical development program.Frontiers in immunology · 2026Review
- Dengue and severe dengue.Clinical microbiology reviews · 2025Review
- Review
- COVID-19 vaccination induces cross-reactive dengue virus antibodies with altered isotype profiles andFrontiers in immunology · 2025Article
- Article
- Article
- Epitope(s) involving amino acids of the fusion loop of Japanese encephalitis virus envelope protein is(are) important to elicit protective immunity.Journal of virology · 2024Article
- Antiviral neutralizing antibodies: from in vitro to in vivo activity.Nature reviews. Immunology · 2023Review
- A Prototype-Pathogen Approach for the Development of Flavivirus Countermeasures.The Journal of infectious diseases · 2023Review
- prM-reactive antibodies reveal a role for partially mature virions in dengue virus pathogenesis.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Antibody-Dependent Enhancement (ADE) and the role of complement system in disease pathogenesis.Molecular immunology · 2022Review
- Antibody Fc characteristics and effector functions correlate with protection from symptomatic dengue virus type 3 infection.Science translational medicine · 2022Article
- Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses.Frontiers in immunology · 2022Review
- Development and Characterization of a Multiplex Assay to Quantify Complement-Fixing Antibodies against Dengue Virus.International journal of molecular sciences · 2021Article
- Whole inactivated dengue virus-loaded trimethyl chitosan nanoparticle-based vaccine: immunogenic properties inHuman vaccines & immunotherapeutics · 2021Article
- C1q binding to surface-bound IgG is stabilized by C1rProceedings of the National Academy of Sciences of the United States of America · 2021Article
- Changes in complement alternative pathway components, factor B and factor H during dengue virus infection in the AG129 mouse.The Journal of general virology · 2021Article
- Monomeric IgA Antagonizes IgG-Mediated Enhancement of DENV Infection.Frontiers in immunology · 2021Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Severe dengue virus infection can occur in humans with pre-existing antibodies against the virus. This observation led to the hypothesis that a subneutralizing antibody level in vivo can increase viral burden and cause more severe disease. Indeed, antibody-dependent enhancement of infection (ADE) in vitro has been described for multiple viruses, including the flaviviruses dengue virus and West Nile virus. Here, we demonstrate that the complement component C1q restricts ADE by anti-flavivirus IgG antibodies in an IgG subclass-specific manner in cell culture and in mice. IgG subclasses that avidly bind C1q induced minimal ADE in the presence of C1q. These findings add a layer of complexity for the analysis of humoral immunity and flavivirus infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.